Merck is moving to expand access to its new HIV prevention medication, but the rollout reveals stark geographic divides in drug affordability across the developing world.
Generic manufacturers in Africa and India will produce cheaper versions of the pill, potentially bringing costs down to just $5 per person annually. That dramatic price point could transform prevention efforts in resource-constrained regions.
The picture looks far murkier for Latin America. Access to the drug and other emerging HIV treatments remains uncertain across much of the region, creating a troubling gap even as the pharmaceutical industry celebrates the breakthrough. Patients and health systems in those countries face unclear pricing, unclear timelines, and unclear pathways to affordable treatment.
The disparity highlights ongoing tensions between drug companies, governments, and global health advocates over how new medicines reach those who need them most. While Merck's licensing approach for generic production in Africa and India represents a significant step toward affordability, it also exposes how piecemeal those efforts remain. Latin America, home to millions at risk, sits in limbo.
The new prevention pill represents genuine scientific progress against HIV. Getting it into the right hands at the right price remains the harder problem.
Author Sarah Mitchell: "Merck deserves credit for the generic licensing strategy, but abandoning Latin America to uncertainty while Africa gets a $5 price tag is a failure of nerve and equity."
Comments